Locally advanced skin cancers of the frail and elderly: consider adaptive split-course radiotherapy

2018 ◽  
Vol 179 (6) ◽  
pp. 1416-1417 ◽  
Author(s):  
G.B. Fogarty ◽  
K.R. McLaren ◽  
Z. Moutrie ◽  
T.S.C. Poon ◽  
M.A. Izard
Keyword(s):  
Locally Advanced ◽  
Skin Cancers ◽  
Split Course Radiotherapy

scholarly journals Attitudes among dermatologists regarding non-melanoma skin cancer treatment options

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Luca Fania ◽  
Tonia Samela ◽  
Gaia Moretta ◽  
Francesco Ricci ◽  
Elena Dellambra ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Treatment Options ◽  
Locally Advanced ◽  
Central Italy ◽  
Therapeutic Approaches ◽  
Antibody Treatment ◽  
Skin Cancers ◽  
Melanoma Skin

AbstractNon-melanoma skin cancers include basal and squamous cell carcinoma. These tumors have become an important health issue for their high incidence and for the morbidity, especially if untreated for a long period. Over the last 20 years, therapeutic approaches for these tumours have been improved and tailored. In this survey we provided data from one hundred and ten Italian dermatologists regarding knowledge and attitude towards different therapeutic approaches on non-melanoma skin cancers. In our study, we observed that surgery and imiquimod 5% cream were the most used treatment by dermatologists for basal cell carcinoma, while, surgery was the most common treatment for cutaneous squamous cell carcinoma. Furthermore, we observed some differences regarding the prescribed therapies in the different Italian geographical areas (i.e., Mohs’ surgery and electrochemotherapy were more frequently used in Northern compared to Central and Southern Italy whereas immunotherapy was more used in Southern compared to Northern and Central Italy) and even considering the year of specialization of the dermatologists (i.e., immunotherapy with cemiplimab was prescribed mainly by dermatologists with 10–19 years of specialization). However, for locally advanced and metastatic forms of basal and squamous cell carcinoma, Hedgehog Pathway Inhibitors and anti- Programmed cell death protein antibody treatment, respectively, were used in line with the newest evolution of therapies regarding this topic. Considering the importance of skin cancers and its progressive increase in incidence, it is crucial to improve the knowledge of different therapeutic approaches among dermatologists.

scholarly journals Adaptive Split Course Radiotherapy for Skin Cancers Decreases Toxicity and Improves Compliance

2017 ◽  
Vol 2 (1) ◽  
Author(s):  
Gerald B Fogarty ◽  
Georgia R Carney ◽  
Karly Rose McLaren ◽  
Zoe Moutrie
Keyword(s):  
Skin Cancers ◽  
Split Course Radiotherapy

scholarly journals Neoadjuvant Therapy for Non-melanoma Skin Cancer: Updated Therapeutic Approaches for Basal, Squamous, and Merkel Cell Carcinoma

2021 ◽  
Vol 22 (4) ◽  
Author(s):  
Enrico Zelin ◽  
Iris Zalaudek ◽  
Marina Agozzino ◽  
Caterina Dianzani ◽  
Arianna Dri ◽  
...  
Keyword(s):  
Targeted Therapy ◽  
Cell Carcinoma ◽  
Merkel Cell Carcinoma ◽  
Checkpoint Inhibitors ◽  
Locally Advanced ◽  
Merkel Cell ◽  
Non Melanoma Skin Cancer ◽  
Skin Cancers ◽  
Multiple Basal Cell Carcinomas ◽  
Melanoma Skin

Opinion statementRecently introduced systemic therapies for locally advanced and metastatic non-melanoma skin cancers (NMSCs) are paving the way for neoadjuvant approach. Although none of the therapeutic options has currently gained indication in this setting, neoadjuvant approach for NMSCs is an open field and we are likely to see huge developments in the near future. Targeted therapy with sonic hedgehog pathway inhibitors is very effective in locally advanced or multiple basal cell carcinomas while immunotherapy with immune checkpoint inhibitors appears to be promising for advanced cutaneous squamous cell carcinoma and Merkel cell carcinoma. To date, targeted therapy and immunotherapy represent the frontiers in NMSC therapeutic management and, according to recent studies, good results can be achieved.

scholarly journals Current Surgical Therapy of Locally Advanced cSCC: From Patient Selection to Microsurgical Tissue Transplant. Review

2021 ◽  
Vol 11 ◽  
Author(s):  
Tito Brambullo ◽  
Gian Paolo Azzena ◽  
Paolo Toninello ◽  
Giuseppe Masciopinto ◽  
Alberto De Lazzari ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Multidisciplinary Approach ◽  
Locally Advanced ◽  
Pedicled Flap ◽  
Node Dissection ◽  
Regional Lymph Nodes ◽  
Skin Cancers ◽  
Ablative Procedures ◽  
Tissue Transplant ◽  
Melanoma Skin

Among the non-melanoma skin cancers (NMSC) the squamous cell carcinoma (SCC) is one of the most challenging for the surgeon. Local aggressiveness and a tendency to metastasize to regional lymph nodes characterize the biologic behavior. The variants locally advanced and metastatic require wide excision and node dissection. Such procedures can be extremely detrimental for patients. The limit of the surgery can be safely pushed forward with a multidisciplinary approach. The concept of skin oncoplastic surgery, the ablative procedures and the reconstructive options (skin graft, pedicled flap, microsurgical free flap) are discussed together with a literature review.

scholarly journals Delayed Response After Confirmed Progression (DR) and Other Unique Immunotherapy-Related Treatment Concepts in Cutaneous Squamous Cell Carcinoma

2021 ◽  
Vol 11 ◽  
Author(s):  
Annette M. Lim ◽  
Karda Cavanagh ◽  
Rodney J. Hicks ◽  
Luke McLean ◽  
Michelle S. Goh ◽  
...  
Keyword(s):  
Squamous Cell ◽  
Locally Advanced ◽  
Second Primary ◽  
Delayed Response ◽  
Specific Response ◽  
Traditional Concept ◽  
Primary Tumors ◽  
Skin Cancers ◽  
Treatment Concepts ◽  
Second Primary Tumors

Non-melanoma skin cancers are one of the most common cancers diagnosed worldwide, with the highest incidence in Australia and New Zealand. Systemic treatment of locally advanced and metastatic cutaneous squamous cell carcinomas has been revolutionized by immune checkpoint inhibition with PD-1 blockade. We highlight treatment issues distinct to the management of the disease including expansion of the traditional concept of pseudoprogression and describe delayed responses after immune-specific response criteria confirmed progressive disease with and without clinical deterioration. We term this phenomenon “delayed response after confirmed progression (DR)”. We also discuss the common development of second primary tumors, heterogeneous disease responses, and expanding clinical boundaries for immunotherapy use.

S177 – Treatment Efficacy of Locally Advanced Skin Cancers

2008 ◽  
Vol 139 (2_suppl) ◽  
pp. P135-P135
Author(s):  
Farhad Ardeshirpour ◽  
Smith J Apisarnthanarax ◽  
Richard Chan Woo Park ◽  
Hayes David ◽  
Julian Rosenman ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Head And Neck ◽  
Locally Advanced ◽  
Disease Free Survival ◽  
Treatment Modalities ◽  
Free Survival ◽  
Skin Cancers ◽  
Number Of Patients ◽  
Alive With Disease ◽  
Single Modality

Objectives To evaluate the treatment outcomes of our patients with locally advanced head and neck non-melatomatous skin cancers (HNNMSC). In this study we determined the 1-and 2-year disease-free survival and the 5-year overall survival of our patients treated with surgery, radiation, and chemotherapy, as a single modality or in combination. Methods Between 1994 and 2006, 197 patients with locally advanced HNNMSC were identified from our institution's Head and Neck Clinical Cancer Database. These patients had their medical records reviewed and of those, 66 met inclusion criteria. We included patients with pathological documentation of locally advanced HNNMSC. Results The majority of these patients were Caucasian and males with an average age of 69 years. 52 patients (79%) had squamous cell carcinoma and 14 (21%) had basal cell carcinoma. 23 patients (35%) received surgery alone, of which 20 (87%) showed no evidence of disease (NED). 5 patients (7%) received radiation alone, all of which showed NED except 1 who is alive with disease. 29 patients (44%) received surgery and radiation, of which 15 (51%) showed NED and the others recurred. 4 patients (6%) had chemotherapy plus radiation, of which 2 recurred. 5 patients (7%) had surgery plus chemotherapy and radiation, of which 2 showed NED, with the others recurred. Conclusions We cannot show statistical differences between different treatment modalities; however, there were more patients with NED in the surgery group compared to surgery and radiation. It is difficult to make conclusions about the chemoradiation because of the small number of patients.

Sign in / Sign up

Export Citation Format

Share Document